Plaque psoriasis: SKYRIZI (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.1
Psoriatic arthritis: SKYRIZI alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs.1
Podcast
July: Episode 1 Watch time: 15 min
Clinical trial spotlight – risankizumab and secukinumab head-to-head in plaque psoriasis
The first episode focuses on the primary publication of IMMerge, a Phase 3, multicentre, randomised, open-label, efficacy assessor-blinded, 52-week study designed to evaluate the safety and efficacy of risankizumab compared with secukinumab in adult patients with moderate to severe plaque psoriasis.2
Podcast Series Host
Dr Laura Savage
University of Leeds and Leeds
Teaching Hospitals NHS Trust
Podcast Guest Speakers
Dr Amy Foulkes
The University of Manchester
Prof Brian Kirby
St Vincent’s University Hospital,
Dublin, Ireland
Podcasts:
References
- SKYRIZI (risankizumab) Summary of Product Characteristics.
- Warren RB, et al. Br J Dermatol Published: Jun 28, 2020. doi: 10.1111/bjd.19341.
UK-RISN-210512 Date of Preparation: November 2021
